The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Kaufman, Robert	en_US
dc.date.accessioned	2012-07-06T20:09:54Z
dc.date.issued	2004	en_US
dc.identifier.citation	The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues (2004 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8963868
dc.description.abstract	The regulation off-label drugs is a complicated and controversial area of the law. Regulators must protect patientsâ€™ safety without interfering with physiciansâ€™ practice of medicine or manufacturersâ€™ First Amendment rights. The recent Neurontin decisions, which apply the doctrine of false claims to prescription drug regulation, only adds additional complexity. This paper explores the federal governmentâ€™s attempts to regulate the promotion of off-label drugs. It discussed the advantages and disadvantages of off-label marketing, the current regulatory environment, and the implications of the Neurontin lawsuit.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	neurontin	en
dc.title	The Neurontin Controversy: The Saga of Off-Label Drug Regulation Continues	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-07-06T20:09:54Z